| 回购方案首次披露日 | 2023/10/12，由公司控股股东深圳华大科技控股集 团有限公司提议 | | --- | --- | | | 待公司第二届董事会第一次会议审议通过后 个 12 | | 回购方案实施期限 | 月 | | 预计回购金额 | 万元~50,000 万元 25,000 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 539.77 万股 | | 累计已回购股数占总股本比例 | 1.2986% | | 累计已回购金额 | 34,995.22 万元 | | 实际回购价格区间 | 元/股~85.99 元/股 39.13 | 证券代码：688114 证券简称：华大智造 公告编号：2024-058 深圳华大智造科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券 ...

中信证券股份有限公司 首次公开发行部分战略配售限售股上市流通的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）作为深圳华大 智造科技股份有限公司（以下简称"华大智造"、"公司"）首次公开发行股票并在 科创板上市的保荐机构，根据《中华人民共和国公司法》《中华人民共和国证券 法》《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》 及《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关 法律、法规和规范性文件的规定，对公司首次公开发行部分限售股及战略配售限 售股上市流通的事项进行了核查，情况如下： 一、本次上市流通的限售股类型 经中国证券监督管理委员会《关于同意深圳华大智造科技股份有限公司首次 公开发行股票注册的批复》(证监许可〔2022〕1638 号)同意，公司向社会公开发 行人民币普通股（A 股）41,319,475 股，并于 2022 年 9 月 9 日在上海证券交易 所科创板挂牌上市。公司首次公开发行 A 股前总股本为 371,790,525 股，首次公 开发行 A 股后总股本为 413,110,000 股，其中有限售条件流通股 381,217,89 ...

证券代码：688114 证券简称：华大智造 公告编号：2024-057 深圳华大智造科技股份有限公司 首次公开发行部分战略配售限售股上市流通的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发战略配售股份（限售期 24 月）；股票认购方式为 网下，上市股数为 1,147,052 股。本公司确认，上市流通数量等于该限售期的全部 战略配售股份数量。 本次股票上市流通总数为 1,147,052 股。 本次股票上市流通日期为 2024 年 9 月 9 日。 一、本次上市流通的限售股类型 经中国证券监督管理委员会《关于同意深圳华大智造科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2022〕1638号）同意，公司向社会公开发 行人民币普通股（A股）41,319,475股，并于2022年9月9日在上海证券交易所科创 板挂牌上市。公司首次公开发行A股前总股本为371,790,525股，首次公开发行A股 后总股本为413,110,000股，其中有限售条件流通股381,217,890 ...

Financial Performance - In the first half of 2024, the company achieved a total revenue of CNY 1.209 billion, a year-on-year decrease of 16% due to macroeconomic factors, geopolitical issues, and market competition [3] - Revenue from instrument equipment was CNY 496 million, down 27% year-on-year; reagent consumables revenue was CNY 624 million, down 5% year-on-year [3] - The gross profit margin for gene sequencers increased to 66%, while the overall gross profit margin improved by 5 percentage points to 63% [3] Gene Sequencing Business - The gene sequencer business generated CNY 1.005 billion in revenue, a year-on-year decrease of 8%, but showed a quarter-on-quarter growth of 24% in Q2 2024 [4] - Revenue from the Chinese mainland and Hong Kong, Macau, and Taiwan regions was CNY 680 million, down 2% year-on-year, but up 33% quarter-on-quarter [4] - The company sold 454 new sequencers in the first half of 2024, marking a historical high for the same period [4] Regional Performance - In the second quarter, the Asia-Pacific region generated CNY 470 million, down 20% quarter-on-quarter due to geopolitical impacts; the Europe and Africa region saw a 42% quarter-on-quarter increase to CNY 790 million [4] - The Americas region generated CNY 410 million, down 3% quarter-on-quarter, affected by the Biosecurity Act [4] Orders and Future Outlook - As of August 22, 2024, the company had an order backlog of CNY 1.001 billion, with gene sequencer orders accounting for 75% [5] - The company expects a positive recovery in the Chinese market in the second half of 2024, driven by strong demand for sequencing platforms [9] - The company is focusing on enhancing its R&D capabilities, particularly in sequencing technology and applications in agriculture and public health [9] Cost Management - The company has implemented stricter cost control measures, resulting in a decrease in management and R&D expenses in Q2 2024 [5] - The gross profit margin for the domestic market was 63%, while the overseas average was 72% [5] Market Conditions - The company is navigating challenges posed by geopolitical tensions and regulatory changes, particularly in the U.S. market, but maintains strong relationships with existing clients [6][7] - The demand for sequencing equipment in hospitals is stable, with potential growth in underdeveloped regions [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company continues to innovate and solidify its competitiveness in the gene sequencing business, with significant improvements in installed capacity and revenue growth in the second quarter of 2024 [1][3] - The company has achieved a revenue of 12.09 billion yuan in the first half of 2024, with a notable increase in the number of installed sequencing instruments [1][3] - The company is focusing on high-throughput and mid-to-low throughput sequencing instruments, which have gained widespread recognition in the market [1][3] Summary by Relevant Sections Financial Performance - In the first half of 2024, the company reported a revenue of 12.09 billion yuan, a year-over-year decrease of 16.23%, with a net profit attributable to the parent company of -2.98 billion yuan [1] - The second quarter of 2024 saw a revenue of 6.78 billion yuan, down 17.70% year-over-year, but with a significant quarter-over-quarter growth of 23.61% [1] - The company’s operating cash flow was -5.78 billion yuan in the first half of 2024 [1] Business Development - The core gene sequencing instrument business generated 10.05 billion yuan in revenue in the first half of 2024, a decrease of 8.40% year-over-year, but with a quarter-over-quarter growth of 23.61% in Q2 2024 [1] - The company added 74 new customers in the domestic sequencing platform, bringing the total to over 940 cooperative users [1] - The company has established over 10 DCS Lab omics frontier laboratories to support global top researchers [2] Future Projections - Revenue is expected to reach 31.46 billion yuan, 37.66 billion yuan, and 45.12 billion yuan for the years 2024, 2025, and 2026, respectively, with year-over-year growth rates of 8.1%, 19.7%, and 19.8% [3] - The net profit attributable to the parent company is projected to improve from -3.17 billion yuan in 2024 to 1.17 billion yuan in 2026, with significant year-over-year growth [3]

| --- | --- | |------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------| | 证券研究报告 | [Table_Title]2024Q2 环比恢复增长，测序仪装机创新高 | | 公司研究 | [Table_ReportDate] 2024 年 08 月 26 日 | | 公司点评报告 Table_ReportType] | [Table_S 事件：公司发布 ummary] 2024 年中报，2024 年上半年实现营业收入 12.09 亿元 | | [Table_StockAndRank] 华大智造(688114) | （yoy-16.23%），实现归母净利润-2.98 亿元（yoy-204.23%），扣非归母 | | 投资评级 | 净利润-3.24 亿元（yoy- ...

Investment Rating - The report maintains a "Recommend" rating for the company (华大智造, stock code: 688114) [1] Core Views - The company's performance in H1 2024 was under pressure, with revenue of 1.209 billion yuan (-16.23% YoY), net profit attributable to shareholders of -298 million yuan, and operating cash flow of -578 million yuan [1] - In Q2 2024, the company's revenue was 678 million yuan (-17.70% YoY), with net profit attributable to shareholders of -97 million yuan and operating cash flow of -359 million yuan [1] - The company's losses narrowed in Q2 2024, attributed to improved efficiency measures [1] - Core business segments showed sequential improvement, with sequencing instrument revenue in H1 2024 reaching 1.005 billion yuan (-8.40% YoY), and a 23.61% QoQ growth in Q2 [1] - The company's R&D investment in H1 2024 was 389 million yuan, accounting for 32.20% of revenue, with a record high of 454 new sequencing instrument installations [1] - The company's global presence expanded, covering 71 countries/regions, with key KOL partnerships increasing [1] - The company announced a restricted stock incentive plan on June 11, 2024, aiming to grant 6.555 million shares (1.58% of total shares) to 325 key personnel [1] Business Performance - Sequencing instrument business: Revenue of 1.005 billion yuan in H1 2024 (-8.40% YoY), with Q2 growth of 23.61% [1] - Laboratory automation business: Revenue of 97 million yuan in H1 2024 (-16.70% YoY), with Q2 growth of 46.47% [1] - New business: Revenue of 88 million yuan in H1 2024 (-60.09% YoY), with Q2 growth of 21.22% [1] - Regional performance: - Mainland China & Hong Kong/Macau/Taiwan: Revenue of 680 million yuan in H1 2024 (-2.20% YoY), with Q2 growth of 32.63% [1] - Overseas regions: Revenue of 325 million yuan in H1 2024 (-19.14% YoY), with growth in Asia-Pacific, Europe/Africa, and Americas regions [1] R&D and Innovation - The company's DNBSEQ-T7 related revenue grew 14.96% YoY in H1 2024, with Q2 growth of 29.02% [1] - DNBSEQ-G99 related revenue grew 82.94% YoY in H1 2024, with Q2 growth of 45.55% [1] - Laboratory automation products saw 212 new installations in H1 2024, with a cumulative total exceeding 4,200 units [1] - Single-cell related revenue in new business grew 220.00% QoQ in Q2 2024 [1] Future Outlook - The company's core business is in a market expansion phase, with significant sales and R&D expenses expected [2] - Revenue growth triggers for 2024 and 2025 are set at 15% and 32%, respectively, with targets of 20% and 44% [2] - The company's domestic scientific research customer transactions increased by over 70% YoY, and hospital coverage increased by 16.09% [2] - The company's U.S. factory began operations, producing the first batch of G99 sequencing instruments [2] - The company signed agreements with related parties to expand its global market presence in spatial transcriptomics and nanopore sequencing [2] Financial Projections - Revenue for 2024E is projected at 3.533 billion yuan, with a growth rate of 21.36% [3] - Net profit attributable to shareholders for 2024E is projected at -244.33 million yuan [3] - Revenue for 2025E is projected at 4.245 billion yuan, with a growth rate of 20.16% [3] - Net profit attributable to shareholders for 2025E is projected at -21.60 million yuan [3] - Revenue for 2026E is projected at 5.078 billion yuan, with a growth rate of 19.61% [3] - Net profit attributable to shareholders for 2026E is projected at 242.86 million yuan [3]

华大智造（688114）/医疗器 械 证券研究报告/公司点评 2024 年 8 月 25 日 评级：买入(维持) 市场价格：39.75 元 分析师：祝嘉琦 执业证书编号：S0740519040001 电话：021-20315150 Email：zhujq@zts.com.cn 分析师：谢木青 执业证书编号：S0740518010004 电话：021-20315895 Email：xiemq@zts.com.cn 分析师：于佳喜 执业证书编号：S0740523080002 Email：yujx03@zts.com.cn 基本状况 | --- | --- | |------------------|--------| | 总股本(百万股) | 416 | | 流通股本(百万股) | 212 | | 市价(元) | 39.75 | | 市值(百万元) | 16,522 | | 流通市值(百万元) | 8,418 | 股价与行业-市场走势对比 华大智造 沪深300 -60% -50% -40% -30% -20% -10% 0% 10% 20% 30% 40% 2023-082023-092023-102023-10 ...